Atara Biotherapeutics (FRA:AT20) Cyclically Adjusted FCF per Share: €-62.76 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AT20 Atara Biotherapeutics Inc FRA:AT20
39 GF Score
Price €7.30
GF Value €1.29
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Cyclically Adjusted FCF per Share?

Atara Biotherapeutics FRA:AT20 +5.80% 39 Cyclically Adjusted FCF per Share is €-62.76 as of Mar. 2026. GuruFocus rates FRA:AT20 with a GF Score™ of 39/100 and a GF Value™ of €1.29 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Atara Biotherapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.189. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-62.76 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Atara Biotherapeutics was -1.60% per year. The lowest was -1.60% per year. And the median was -1.60% per year.

As of today (2026-07-17), Atara Biotherapeutics's current stock price is €7.30. Atara Biotherapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-62.76. Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF of today is .


Atara Biotherapeutics  (FRA:AT20) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Atara Biotherapeutics Cyclically Adjusted FCF per Share Related Terms


Atara Biotherapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Cyclically Adjusted FCF per Share Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -69.13 -78.00 -57.09 -65.79

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.92 -71.50 -65.92 -65.79 -62.76

FRA:AT20 vs ANIX, BMEA, PMN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:AT20
39GF Score
Atara Biotherapeutics Inc FRA:AT20
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atara Biotherapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.189/330.2130*330.2130
=-0.189

Current CPI (Mar. 2026) = 330.2130.

Atara Biotherapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -8.951 241.018 -12.264
201609 -12.351 241.428 -16.893
201612 -18.156 241.432 -24.832
201703 -18.701 243.801 -25.329
201706 -17.827 244.955 -24.032
201709 -18.186 246.819 -24.331
201712 -23.872 246.524 -31.976
201803 -27.970 249.554 -37.010
201806 -22.610 251.989 -29.629
201809 -24.821 252.439 -32.468
201812 -29.550 251.233 -38.840
201903 -34.055 254.202 -44.238
201906 -26.367 256.143 -33.992
201909 -22.166 256.759 -28.507
201912 -23.944 256.974 -30.768
202003 -25.278 258.115 -32.339
202006 -19.175 257.797 -24.561
202009 -13.979 260.280 -17.735
202012 -1.136 260.474 -1.440
202103 -15.591 264.877 -19.437
202106 -14.330 271.696 -17.416
202109 -14.265 274.310 -17.172
202112 -8.340 278.802 -9.878
202203 -19.637 287.504 -22.554
202206 -15.178 296.311 -16.915
202209 -16.071 296.808 -17.880
202212 -13.016 296.797 -14.481
202303 -8.720 301.836 -9.540
202306 -11.701 305.109 -12.664
202309 -11.366 307.789 -12.194
202312 -10.701 306.746 -11.520
202403 -4.866 312.332 -5.145
202406 -1.614 314.175 -1.696
202409 -0.481 315.301 -0.504
202412 -2.190 315.605 -2.291
202503 -2.399 319.799 -2.477
202506 -0.515 322.561 -0.527
202509 -0.615 324.800 -0.625
202512 -0.350 324.054 -0.357
202603 -0.189 330.213 -0.189

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-62.76 mean?
Atara Biotherapeutics (FRA:AT20) has a Cyclically Adjusted FCF per Share of €-62.76 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Cyclically Adjusted FCF per Share too high?
Atara Biotherapeutics' current Cyclically Adjusted FCF per Share is €-62.76. Overall, Atara Biotherapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Cyclically Adjusted FCF per Share compare to ANIX and BMEA?
Atara Biotherapeutics' Cyclically Adjusted FCF per Share of €-62.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Cyclically Adjusted FCF per Share is €-62.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (FRA:AT20) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.29, compared to a current price of €7.30 — trading 465.9% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-62.76. Atara Biotherapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Atara Biotherapeutics (FRA:AT20), the current Cyclically Adjusted FCF per Share is €-62.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (FRA:AT20) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of €7.30 is trading 465.9% above its estimated GF Value™ of €1.29. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for FRA:AT20:

  • Cyclically Adjusted FCF per Share: €-62.76
  • GF Value™: €1.29 vs. price of €7.30 (465.9% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the FRA:AT20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atara Biotherapeutics Business Description

Other Exchanges ATRA:USA0HIY:UK
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
39GF Score

Get the complete analysis for FRA:AT20

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.30
Price
€1.29
GF Value